BBLG Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
808.1K
+0.4%
805.1K
+9.8%
733.1K
+2.5%
715.3K
-4.4%
748.1K
R&D
308.7K
+118.0%
141.6K
-44.9%
257.2K
+36.9%
187.8K
-2.0%
191.6K
SG&A
499.4K
-24.7%
663.5K
+39.4%
475.9K
-9.8%
527.5K
-5.2%
556.5K
Operating Income
-808106
-0.4%
-805054
-9.8%
-733105
-2.5%
-715274
+4.4%
-748075
EBITDA
-808106
-0.4%
-805054
-9.8%
-733105
-2.5%
-715274
+4.4%
-748075
Net Income
-773702
-1.0%
-765988
-11.9%
-684643
-2.7%
-666737
+10.0%
-740519
EPS (Basic)
$-0.43
+0.0%
$-0.43
-13.2%
$-0.38
-2.7%
$-0.37
+72.2%
$-1.33
EPS (Diluted)
$-0.43
+0.0%
$-0.43
-13.2%
$-0.38
-2.7%
$-0.37
+72.2%
$-1.33
Shares (Diluted)
1.8M
+0.1%
1.8M
-1.1%
1.8M
+1.2%
1.8M
+221.8%
557.8K
Bone Biologics (BBLG) โ€” Financials